In an antigen-induced arthritis model, Cerk-/- mice were not protected, thus inconsistent with the hypothesis that C1P made by CERK is key for cPLA2 activation in vivo -- parallel pharmacological inhibition of cPLA2 could indeed dampen disease development [3]. The gene discussed is CERK; the disease is arthritic joint disease.